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Abstract
Background A radical left pancreatectomy in patients with pancreatic ductal adenocarcinoma (PDAC) may require extended, 
multivisceral resections. The role of a laparoscopic approach in extended radical left pancreatectomy (ERLP) is unclear 
since comparative studies are lacking. The aim of this study was to compare outcomes after laparoscopic vs open ERLP in 
patients with PDAC.
Methods An international multicenter propensity-score matched study including patients who underwent either laparoscopic 
or open ERLP (L-ERLP; O-ERLP) for PDAC was performed (2007–2015). The ISGPS definition for extended resection was 
used. Primary outcomes were overall survival, margin negative rate (R0), and lymph node retrieval.
Results Between 2007 and 2015, 320 patients underwent ERLP in 34 centers from 12 countries (65 L-ERLP vs. 255 
O-ERLP). After propensity-score matching, 44 L-ERLP could be matched to 44 O-ERLP. In the matched cohort, the con-
version rate in L-ERLP group was 35%. The L-ERLP R0 resection rate (matched cohort) was comparable to O-ERLP (67% 
vs 48%; P = 0.063) but the lymph node yield was lower for L-ERLP than O-ERLP (median 11 vs 19, P = 0.023). L-ERLP 
was associated with less delayed gastric emptying (0% vs 16%, P = 0.006) and shorter hospital stay (median 9 vs 13 days, 
P = 0.005), as compared to O-ERLP. Outcomes were comparable for additional organ resections, vascular resections (besides 
splenic vessels), Clavien–Dindo grade ≥ III complications, or 90-day mortality (2% vs 2%, P = 0.973). The median overall 
survival was comparable between both groups (19 vs 20 months, P = 0.571). Conversion did not worsen outcomes in L-ERLP.
Conclusion The laparoscopic approach may be used safely in selected patients requiring ERLP for PDAC, since morbidity, 
mortality, and overall survival seem comparable, as compared to O-ERLP. L-ERLP is associated with a high conversion rate 
and reduced lymph node yield but also with less delayed gastric emptying and a shorter hospital stay, as compared to O-ERLP.
Keywords Left pancreatectomy · Extended resection · ERLP · PDAC
Abbreviations
ERLP  Extended radical left pancreatectomy
L-ERLP  Laparoscopic extended radical left 
pancreatectomy
O-ERLP  Open extended radical left pancreatectomy
PDAC  Pancreatic ducal adenocarcinoma
ISGPS  International study group on pancreatic surgery
POPF  Postoperative pancreatic fistula
ASA  American society of anesthesiologists
and Other Interventional Techniques 
A. Balduzzi and J van Hilst: Shared first authorship; M. Abu Hilal 
and M. G. Besselink: Principal investigators and shared senior 
authors.
Supplementary information The online version of this article 
(https ://doi.org/10.1007/s0046 4-020-08206 -y) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
 Surgical Endoscopy
1 3
Pancreatic ductal adenocarcinoma (PDAC) in the pancreatic 
body and tail is frequently (~ 30%) associated with adjacent 
organ/vessel invasion [1–3]. Patients with a tumor extending 
beyond the pancreas may still be considered for surgery based 
on the extent and type of organ/vessel invasion, especially 
after neoadjuvant treatment. An extended radical left pancrea-
tectomy is defined according to the resection margins (includ-
ing transection and circumferential margins), Gerota’s fascia 
resection, and a formal lymphadenectomy [4]. Several cohort 
studies have shown that open extended radical left pancreatec-
tomy (O-ERLP) can be associated with acceptable morbidity 
and mortality rates and improved overall survival when com-
pared to patients undergoing palliative surgery [5–8].
Minimally invasive left pancreatectomy is gaining popu-
larity [9–11] with recently the first randomized controlled 
multicenter trials confirming improved time to functional 
recovery and shorter hospital stay as compared to open distal 
pancreatectomy [9, 12].
In recent years, indications for laparoscopic left pancre-
atectomy have been broadened [13], and techniques have 
been standardized with excellent results [14, 15]. Moreover, 
laparoscopic ERLP (L-ERLP) is now regularly performed 
in experienced centers for selected patients with PDAC 
necessitating resections extending beyond the pancreas and 
spleen. However, studies comparing the surgical and onco-
logical outcomes between L-ERLP and O-ERLP are lacking.
The current study aims to evaluate the surgical and onco-
logical outcomes following L-ERLP and O-ERLP for PDAC 
through a propensity-score matched analysis.
Materials and methods
Patients and design
This international multicenter retrospective cohort study 
was performed among centers of the European consortium 
for Minimally Invasive Pancreatic Surgery (E-MIPS) [16]. 
Patients were included from 34 centers in 11 European coun-
tries and one center from the USA. All consecutive patients 
who underwent laparoscopic or open distal pancreatectomy 
(no robotic procedures were included) with a histopathologi-
cal diagnosis of PDAC between January 1, 2007 and July 
1, 2015 were screened for inclusion (Fig. 1). Patients were 
Fig. 1  Study flow-chart
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included if they underwent an extended left pancreatectomy. 
Patients were excluded if they had a previous pancreatic 
resection or if distant metastases were present at the time of 
surgery. Patients were categorized according to the method 
of surgery: L-ERLP and O-ERLP. The ethics committee of 
the Amsterdam UMC, location Academic Medical Center, 
waived the need for informed consent because of the obser-
vational study design. This study was performed according 
to the Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) guidelines [17].
Data collection
Any type of additional organ (e.g., stomach, colon) or vas-
cular resection (e.g., superior mesenteric vein) was collected 
from the operative reports and were individually reported by 
each center into the database. Overall survival was, depend-
ing on the center, either collected from patient records, 
municipal personal records database, or by personal contact 
with patient or family. All data were stored and processed 
anonymously.
Definitions
Extended resection was defined according to the definition 
of International Study Group for Pancreatic Surgery (ISGPS) 
and included any of the following additional resections: par-
tial/wedge gastrectomy, colon and/or mesocolon including 
relevant vascular structures of the mesocolon (transverse, 
middle colic vessels), small bowel, portal, superior mesen-
teric and/or inferior mesenteric vein, hepatic artery, celiac 
axis, and/or superior mesenteric artery, inferior vena cava, 
left adrenal gland, left kidney and/or its vasculature, liver, 
diaphragm, and diaphragmatic crura [18]. Margins were 
categorized according to the Royal College of Patholo-
gists definition and classified into R0 (distance margin to 
tumor ≥ 1 mm), R1 (distance margin to tumor < 1 mm), 
and R2 (macroscopically positive margin) [19]. Postop-
erative complications were scored and classified using the 
Clavien–Dindo classification [20]. Major complications 
were defined as Clavien–Dindo grade III or higher [21]. 
The ISGPS definitions were used to classify postoperative 
pancreatic fistula (POPF), delayed gastric emptying (DGE), 
and postpancreatectomy hemorrhage (PPH) [22–24]. ISGPS 
grade B/C complications were considered clinically relevant 
and only these were noted. Conversion was defined as any 
laparotomy or hand assistance for other reasons than trocar 
placement or specimen extraction. We defined as high vol-
ume a center performing more than 15 MI DP during the 
study period according to the 75-percentile value.
Statistical analysis
Data were analyzed using IBM SPSS Statistics for Win-
dows version 26.0 (IBM Corp., Orchard Road Armonk, 
New York, US). Data were analyzed according to the 
intention-to-treat principles, meaning that outcomes of a 
converted minimally invasive procedure were analyzed in 
the minimally invasive group. Categorical data are pre-
sented as percentages and frequencies and were compared 
using the Chi-square or Fisher’s exact test as appropri-
ate. Normally distributed continuous data are presented as 
means and standard deviations (SDs) and were compared 
using the two-sided independent samples t test. Non-nor-
mally distributed continuous data are presented as medians 
and interquartile ranges (IQRs) and were compared using 
the Mann–Whitney U test. All analyses were performed 
in both the total cohort and the propensity-score matched 
cohort. Propensity-score matching was applied in order to 
achieve balanced groups with comparable baseline charac-
teristic and potentially minimizing confounding [25]. Mul-
tivariable logistic regression was performed to estimate 
the propensity to undergo e-MILP for all patients, regard-
less of the actual treatment received. Propensity scores 
were based on age, body mass index (BMI), American 
society of anesthesiologists (ASA), tumor location, larg-
est tumor size, neoadjuvant chemotherapy, neoadjuvant 
radiotherapy, and vascular resection. Nearest neighbor 
matching was performed in a 1:1 ratio without replace-
ment and a caliper width of 0.01 standard deviation (SD) 
was specified. In order to assess the differences between 
the analyzed cohorts, we used the standardized mean dif-
ference (SMD). An SMD of 0 indicates that there are no 
differences between the two populations; an SMD of 0.2, 
0.5, and 0.8 indicates a small, medium, or large difference 
between the two cohorts, respectively.
Sensitivity analyses
Sensitivity analyses were conducted from the matched 
cohort. According to the ISGPS definition, adrenal gland 
resection is defined as an extended resection. Resection 
of the adrenal gland is also performed as part of radical 
antegrade modular pancreatosplenectomy (RAMPS) [26]. 
Therefore, the first sensitivity analysis excluded patients 
with only an adrenal gland resection. Additionally, since 
laparoscopic vascular resection is considered highly 
advanced surgery, a second additional sensitivity analy-
sis was performed excluding patients with laparoscopic 
or open vascular resections. A third sensitivity analysis 
was performed comparing converted L-ERLP patients to 
L-ERLP and O-ERLP. A fourth sensitivity analysis was 
performed comparing outcomes in high- and low-volume 
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A total of 1297 patients with PDAC of the body and tail 
of the pancreas who underwent a left pancreatectomy were 
screened. Of all patients, 320 underwent ERLP and were 
included in the present study: 65 patients (20%) under-
went L-ERLP and 255 O-ERLP (80%). Less patients in the 
L-ERLP group received preoperative chemotherapy (2% vs 
17%, 0.001), as shown in Table 1. Conversion from L-ERLP 
to open surgery occurred in 23 patients (36%), mainly for 
intraoperative findings of tumor extension (43%). Operative 
outcomes for the total cohort are shown in Table 2. Intra-
operative blood loss was lower for L-ERLP [300 mL (IQR 
100–775) vs 400 mL (IQR 200–800, P = 0.021)]. Median 
lymph node retrieval was lower in the L-ERLP group [14 
(IQR 7–24) vs 18 (IQR 11–29) nodes, P = 0.014]. R0 resec-
tion rates were comparable after L-ERLP and O-ERLP 
(69% vs 56%, P = 0.061), but L-ERLP showed a lower rate 
of positive circumferential margins compared to O-ERLP 
(24% vs 55%, P = 0.000). After 2015, R0 rate was higher in 
L-ERLP group (92.3% vs 48.5%, P < 0.006). Gerota’s fascia 
resection (37% vs 46%, P = 0.007) and splenectomy (95% 
vs 99%, P = 0.027) were performed less frequently in the 
L-ERLP group. The main pathological features for the total 
cohort are shown in Table 3. L-ERLP was associated with a 
3-day shorter hospital stay [9 (IQR 6–14) vs 12 days (IQR 
Table 1  Baseline characteristics
ASA indicates American Society of Anesthesiologists, BMI body mass index, IQR interquartile range, L-ERLP laparoscopic extended radical left 
radical pancreatectomy, O-ERLP open extended radical left pancreatectomy, SD standard deviation
# Fisher’s exact test was used










Female, n (%) 29 (44) 124 (49) 0.563 – 19 (43) 22 (50) 0.521 − 0.14
 Unknown – – 0.08 – –
Age, year, mean (SD) 69 (9) 67 (10) 0.044 0.1 69 (9) 67 (8) 0.186 0.20
 Unknown, n (%) – – 7 – –
BMI, kg/m2, median (SD) 26 (4) 25 (4) 0.605 0.1 25 (4) 25 (4) 0.822 0
 Unknown 9 (14) 21 (8) 7 – –
Previous abdominal surgery, n (%) 14 (25) 74 (34) 0.190 – 9 (21) 10 (29) 0.469 − 0.18
 Unknown 8 (12) 35 (14) 0.19 2 (5) 9 (20)
ASA physical status, n (%)
 1 3 (5) 21 (9) 0.12 2 (5) 1 (2) 0.831 − 0.10
 2 40 (62) 158 (64) 29 (66) 29 (66)
 3 21 (34) 66 (27) 13 (29) 14 (32)
 4 0 (0) 3 (1) 0 (0) 0 (0)
 Unknown 1 (1) 7 (3) – –
Tumor location, n (%)
 Body 24 (44) 131 (52) 0.488 0.10 18 (41) 24 (55) 0.116 0.18
 Body-tail junction 0 (0) 20 (8) 0 (0) 0 (0)
 Tail 31 (56) 103 (41) 0 (0) 0 (0)
 Unknown 10 (15) 1 (0) – –
Tumor size on imaging, mm,
 Median (IQR) 38 (26–46) 42 (30– 50) 0.023 0.2 35 (25–49) 35 (25–49) 0.848 0.06
 Unknown 8 (12) 47 (17) 2 − 1 (2) − 1 (2)
Neoadjuvant therapy, n (%)
 Chemotherapy 1 (2) 44 (17) < 0.001# − 0.80 0 (0) 0 (0) > 0.999 0
 Unknown 2 (3) – 0.365# 0 (0) 0 (0)
 Radiotherapy 0 (0) 8 (3) 0 (0) 0 (0) –
 Unknown 1 (1) –
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8–19), P = 0.001] and showed a 10% lower rate of DGE (2% 
vs 12%, P = 0.015). Median overall survival was 21 months 
(95% CI 14–28) after L-ERLP and 22 months (95% CI 
17–26) after O-ERLP (P = 0.566). The postoperative out-
comes for the total cohort are shown in Table 4.   
Matched cohort
After calculating the propensity scores for each patient, 44 
patients after L-ERLP (68%) were successfully matched 
to 44 O-ERLP (17%) controls. Baseline characteris-
tics were comparable after matching and improvement 
of SMDs were observed, as shown in Table 1. Intraop-
erative outcomes are shown in Table 2. Conversion from 
L-ERLP to O-ERLP occurred in 16/44 patients (35%). 
Additional organ resection (77% vs 68%, P = 0.338) and 
vascular resection (21% vs 25%, P = 0.611) were compa-
rable between the L-ERLP and O-ERLP group. A 28% 
lower rate of Gerota’s fascia resection was observed in 
the L-ERLP group (31% vs 59%, P = 0.011). A lower 
median number of lymph nodes retrieved was observed 
in the L-ERLP group [11 (IQR 6–22) vs 19 (IQR 11–30), 
P = 0.023], while the R0 resection rate comparable (67% 
vs 48%, P = 0.063). However, L-ERLP showed a lower rate 
of positive circumferential margins compared to O-ERLP 
(23% vs 61%, P = 0.002). Postoperative complications 
were comparable between groups, as shown in Table 4. 
Hospital stay was 4 days shorter after L-ERLP [9 (IQR 
Table 2  Operative outcomes
DP indicates left pancreatectomy, IQR interquartile range, L-ERLP laparoscopic extended radical left radical pancreatectomy, O-ERLP open 
extended radical left pancreatectomy, SMV superior mesenteric vein, IMV inferior mesenteric vein
**In some procedures multiple organ resections were performed
***Procedure with additional vascular resection besides splenic vessels
# Fisher’s Exact test was used










Conversion, n (%) 23 (36) – – 16 (35) – –
 Unknown – – 1 (2) –
  Because of bleeding − 4 (26) – 3 (7) –
  Tumor extension 10 (43) – 8 (18) –
  Vascular involvement 6 (26) – 4 (9) –
  Other 3 (5) – 1 (2)
Operative time, min, median (IQR) 282 (198–364) 286 (225–345) 0.342 240 (195-322) 280 (222-379) 0.107
 Unknown 1 4 1 (2) 1 (2)
Intraoperative blood loss, mL
 Median (IQR) 300 (100–775) 400 (200–800) 0.021 290 (70-650) 333 (130-700) 0.495
 Unknown 9 78 4 (9) 9 (21)
Splenectomy, n (%) 62 (95) 252 (99) 0.027 43 (98) 42 (96) 0.557
 Unknown – 1 (0) – –
Gerota’s fascia resection, n (%) 22 (37) 129 (46) 0.007 13 (31) 24 (59) 0.011
 Unknown 6 (27) 28 (17) 2 (5) 3 (7)
Additional organ resection**, n (%) 50 (77) 166 (65) 0.069 34 (77) 30 (68) 0.338
 Adrenal gland resection 34 (52) 76 (30) 21 (48) 12 (27)
 Nephrectomy (partial) 7 (11) 18 (7) 5 (11) 7 (16)
 Colectomy (partial) 13 (20) 57 (22) 11 (25) 11 (25)
 Small bowel (partial) 6 (9) 22 (9) 3 (7) 5 (11)
 Gastrectomy (total) 4 (6) 35 (14) 3 (7) 10 (23)
 Gastrectomy (partial) 7 (11) 41 (16) 4 (9) 6 (14)
Vascular resection***, n (%) 16 (25) 96 (38) 0.049 9 (21) 11 (25) 0.611
Unknown – – – –
 Portomesenteric vein/SMV/IMV 12 (63) 84 (85) 8 (18) 10 (63)
 Celiac trunk 4 (6) 13 (5) 1 (2) 1 (2)
 Hepatic artery 0 (0) 7 (3) 0 (0) 1 (2)
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6–13) vs 13 days (IQR 8–23), P = 0.005] and the rate of 
DGE was 16% lower in the L-ERLP group compared to the 
O-ERLP group (0% vs 16%, P = 0.006). The median over-
all survival was 19 months (95% CI 14–24) after L-ERLP 
and 20 months (95% CI 9–31) after O-ERLP (P = 0.571). 
The median overall survival of R0 patients was 14 months 
in the L-ERLP group (95% CI 6–23) and 50 months in 
the O-ERLP group (95% CI–103), P = 0.62 (Fig.  2). 
Median overall survival of R1 patients was 19 months 
in the L-ERLP group (95% CI 11–27) and 17 months 
in the O-ERLP group (95% CI 6–28), P = 0.25. Median 
time to start of chemotherapy was 49 days (IQR 37–63) 
after L-ERLP and 55 days (IQR 35–69) after O-ERLP 
(P = 0.758). Median time to recurrence was 5 months (95% 
CI 3.7–6.3) after L-ERLP and 6 months (95% CI 3.3–8.7) 
after O-ERLP (P = 0.467).
Sensitivity analyses
Sensitivity analyses are shown in Supplementary Tables 
S5–S16.
The first sensitivity analysis excluding patients with only 
an adrenal gland resection increased the conversion rate of 
L-ERLP from 35 to 50%. L-ERLP remained associated with 
less DGE (0% vs 16%, P = 0.047), as compared to O-ERLP. 
Pathology outcomes were comparable between groups (Sup-
plementary Table S7).
In the second sensitivity analysis, excluding patients 
with vascular resection, no differences were found between 
L-ERLP and O-ERLP in baseline characteristics, operative 
outcomes, and pathology (Supplementary Tables S9, S10, 
S11). The conversion rate of L-ERLP was 26%. L-ERLP 
showed a lower lymph node yield [9 (IQR 5–18) vs 18 
Table 3  Pathology outcome
IQR indicates interquartile range; L-ERLP laparoscopic extended radical left radical pancreatectomy, O-ERLP open extended radical left pan-
createctomy
**Defined as a microscopic radical resection with a distance between the tumor and the margin of ≥ 1 mm










Tumor size, mm, median (IQR) 40 (30–55) 40 (30–60) 0.789 40 (25–60) 40 (26–50) 0.424
 Unknown 3 (5) 6 (2) 1 (2) –
Tumor stage 0.236 0.093
 T1 0 (0) 11 (5) 0 (0) 3 (7)
 T2 9 (14) 22 (9) 7 (16) 3 (7)
 T3 46 (70) 179 (70) 32 (73) 34 (77)
 T4 7 (11) 29 (11) 4 (9) 1 (2)
 Unknown 3 (5) 15 (5) 1 (2) 3 (7)
Lymph node stage 0.054
 N0 23 (37) 76 (31) 0.362 16 (37) 8 (17)
 N1 40 (64) 173 (70) 27 (63) 35 (81)
 Unknown 2 (3) 6 (2) 0.207 40 (93) 1 (2)
Metastasis
 M0 59 (91) 223 (87) 3 (7) 38 (86) 0.308
 M1 4 (6) 30 (12) 1 (2) 6 (14)
 Unknown 2 (3) 2 (1) –
Lymph nodes retrieved, median (IQR) 14 (7–24) 18 (11–29) 0.014 11 (6–22) 19 (11-30) 0.023
Tumor positive lymph nodes, median (IQR) 1 (0–3) 1.5 (0–3) 0.711 1 (0–3) 2 (1-3) 0.188
 Unknown 4 3 – –
R0 resection**, n (%) 44 (69) 139 (56) 0.061 29 (67) 21 (48) 0.063
 Unknown 6 (2) 1 (2) 1 (2) –
Positive transection margins, n (%) 8 (14) 23 (12) 0.599 7 (18) 2 (6) 0,151
Positive circumferential margins, n (%) 12 (24) 101 (55) 0.000 8 (23) 19 (61) 0.002
Lymphovascular invasion, n (%) 39(63) 163 (69) 0.332 28 (67) 24 (60) 0.531
 Unknown 3 (5) 20 (8) 2 (4) 4 (9)
Perineural invasion, n (%) 51 (81) 201 (83) 0.694 36 (84) 32 (80) 0.660
 Unknown 2 (3) 13 (5) 1 (2) 4 (9)
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(10–28), P = 0.045], lower DGE rate (0% vs 18%, P = 0.008), 
and shorter hospital stay [9 (IQR 6–13) vs 11 (IQR 8–23) 
days, P = 0.009] compared to the O-ERLP group.
The third sensitivity analysis, comparing patients who 
underwent converted L-ERLP to totally laparoscopic ERLP, 
showed a lower number of additional organ resection (56% 
vs 93%, P = 0.005) (Table S14) but a higher rate of vascular 
resection (44% vs 4%, P = 0.001). No differences were seen 
between converted ERLP and O-ERLP in baseline charac-
teristics, operative outcomes, pathology outcomes, and post-
operative outcomes, as shown in Supplementary Tables S13, 
S14, S15, and S16.
The fourth sensitivity analysis excluding low-volume 
centers (< 15 minimally invasive distal pancreatectomies) 
and high-volume center (> 15 minimally invasive distal pan-
createctomies) (Supplementary Tables S17, S18, S19, and 
S20) found a lower conversion rate in high-volume cent-
ers (28% vs 55%, P = 0.024), as well as a shorter operative 
time [227 (IQR 181–286) vs 289 (217–366), P = 0.028] and 
length of hospital stay [5 (4–7) vs 11 (9–14), P = 0.035], as 
compared to low-volume centers.
Discussion
This first international multicenter propensity-score matched 
study on laparoscopic versus open ERLP for PDAC showed 
comparable overall survival and R0 resection rates for 
Table 4  Postoperative outcome
IQR interquartile range, L-ERLP laparoscopic extended radical left radical pancreatectomy, O-ERLP open extended radical left pancreatectomy
*According to the International Study Group on Pancreatic Fistula definition
**According to the International Study Group on Pancreatic Surgery definition










Clavien–Dindo score ≥ III complications, n (%) 20 (31) 81 (32) 0.877 11 (25) 15 (34) 0.350
 Unknown – – – –
Postoperative pancreatic fistula grade B/C*, n (%) 13 (20) 69 (27) 0.245 7 (16) 13 (30) 0.127
 Unknown – – – –
Delayed gastric emptying grade B/C**, n (%) 1 (2) 30 (12) 0.015# 0 (0) 7 (16) 0.006*
 Unknown 2 – – –
Post pancreatectomy hemorrhage grade B/C**, n (%) 5 (8) 10 (4) 0.178 4 (9) 1 (2) 0.167
 Unknown 2 – – –
Surgical site infection, n (%) 3 (5) 20 (8) 0.464 2 (5) 1 (2) 0.557
 Unknown 6 – – –
Length of hospital stay, d, median (IQR) 9 (6–14) 12 (8–19) 0.001 9 (6-13) 13 (8-23) 0.005
 Unknown 2 (3) 4 (2) 1 (2) –
Readmission, n (%) 9 (15) 37 (16) 0.810 5 (12) 9 (24) 0.166
 Unknown 4 24 2 (5) 6 (14)
90-day mortality, n (%) 2 (3) 10 (4) 0.687 1 (2) 1 (2) 0.973
 Unknown 1 (2) 19 (8) – 2 (5)
Adjuvant chemotherapy, n (%) 41 (71) 150 (73) 0.749 30 (71) 30 (79) 0.438
 Unknown 7 (11) 49 (19) 0.914 2 (5) 6 (14) 0.758
Time until start adjuvant chemotherapy, d, median (IQR) 55 (35–69) 57 (39–63) 49 (37-63) 55 (35-69)
 Unknown 37 (52) 174 (54) 19 (43) 25 (57)
Fig. 2  Survival analysis (matched cohort)
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both groups. However, the high conversion rate, less resec-
tions of Gerota’s fascia, and fewer lymph nodes retrieved 
in the L-ERLP group warrants further investigation. In 
the L-ERLP group, the overall length of hospital stay was 
shorter and rates of DGE were lower in the matched cohort 
as compared to the O-ERLP group.
Extended resections are associated with worse outcomes 
compared to standard left pancreatectomy resections. In a 
recent multicenter retrospective study, Sahakyan et al. [27] 
analyzed 191 patients with PDAC undergoing laparoscopic 
left pancreatectomy (154 standard and 30 extended). The two 
cohorts differed in tumor size (30 vs 45 mm in the extended 
group, P = 0.001) and recurrence rate (37% vs 63% in the 
extended group, P = 0.009). Patients undergoing an extended 
resection had a higher rate of undesired intraoperative inci-
dents (15.5% vs 35.5% in the extended group) and a higher 
conversion rate (6% vs 13.3% in the extended group). A 
study from the Oslo group [28] included 81 patients under-
going extended laparoscopic DP (22 patients) and standard 
laparoscopic DP (59 patients) for PDAC. In this study, the 
median recurrence-free and overall survival were shorter for 
the extended laparoscopic DP group compared to the stand-
ard laparoscopic DP group (6.2 vs 9.6 months, P = 0.047 
and 12.9 vs 27 months, P < 0.01, respectively). Extended 
laparoscopic DP was associated with a longer operative time 
and higher conversion rate (16% vs 3%, P = 0.019) compared 
to standard laparoscopic DP but no differences in postopera-
tive morbidity, mortality, and hospital stay were observed. 
The authors suggested that extended laparoscopic DP could 
be, in experienced hands, an alternative to open resection or 
used as palliative care only in selected cases.
In the present study, less lymph nodes were retrieved and 
Gerota’s fascia was less often resected in the L-ERLP group, 
although the R0 resection rate was comparable between both 
approaches. Concerns regarding the oncological safety of 
L-ERLP for PDAC in general remain as confirmed by a 
recent survey [29] where 30% of surgeons would expect 
laparoscopic left pancreatectomy to be inferior to the open 
approach concerning oncological safety. In this survey, vas-
cular resection was performed less frequently in the lapa-
roscopic approach (6% vs 11%, P = 0.012), probably due to 
patient selection.
Our study showed comparable overall survival between 
both techniques. Standardized minimally invasive techniques 
for PDAC have been described [15] and radical resection 
rates can be improved using the RAMPS technique [14, 
26]. Nevertheless, the present study showed a lower rate 
of Gerota’s fascia resection in the L-ERLP group, both 
before and after matching. This could be due to the long 
study period, with patients included from 2007, before 
safety, feasibility, and specific tips and tricks for performing 
L-ERLP were published [15]. However, despite matching, 
probably patients with less extensive tumors are included in 
the L-ERLP group which could explain why Gerota’s fascia 
was less often resected but this is speculative. These out-
comes are in line with those reported for standard (i.e., non-
extended) laparoscopic vs open distal pancreatectomy [16].
Studies comparing outcomes after L-ERLP and O-ERLP 
are scarce. The conversion rate in the present study is high 
(36% in the matched cohort,) compared to available studies 
showing a conversion rate of 13.3% [27]. This might repre-
sent the consequence of the learning curve and the broaden-
ing of the indications for laparoscopic distal pancreatectomy 
for neoplasms with extension to vascular structures requiring 
an accurate vascular control for reconstruction. Moreover, 
many centers may attempt a laparoscopic approach with a 
low threshold for conversion to the open approach in case 
of unexpected multivisceral resection. Potentially, conver-
sion rates will lower in future studies due to the growing 
experience with L-ERLP. Also, use of robotic surgery could 
lower the conversion rate as has been suggested by a recent 
systemic review [30].
The adrenal gland was resected more often during 
L-ERLP compared to O-ERLP (11% vs 6%, P = 0.029). 
Since the ISGPS definition includes adrenal gland resection 
as extended resection, it was expected that these patients 
maybe had less extensive tumors and adrenal gland resection 
was performed at a low threshold. However, we did not find 
any difference in pathology outcomes (tumor size, stage, 
and lymph nodes harvested) excluding patients with only 
adrenal gland resection. It could also be that the laparoscopic 
approach facilitates resection of the adrenal gland which can 
(more) easily be seen in the posterior plane due to laparo-
scopic vision. Nevertheless, the conversion rate in this sensi-
tivity analysis was even higher (50%) which is probably the 
result of excluding the relatively minor extended resections.
The outcomes of the present study should be interpreted 
with several limitations in mind. First, data were collected 
retrospectively which could have influenced the quality of 
data. Second, despite the efforts to minimize allocation bias 
by propensity-score matching, some differences in baseline 
characteristics remained which could have influenced out-
comes. For example, it could be that less invasive tumors are 
included in the L-ERLP group. This could explain some of 
the finding such as the lower tumor and lymph node stage. 
However, given the large number of centers involved in this 
study, we could not reliably assess the selection criteria for 
the laparoscopic approach. Third, the R0 resection rate was 
comparable between L-ERLP and O-ERLP, but this could 
be due to the small sample size of the study. Prospective data 
from international registry studies are necessary to compare 
these data. Currently, the E-MIPS registry (www.e-mips.
com/regis try) is prospectively collecting data on all patients 
undergoing minimally invasive pancreatic surgery in cent-
ers throughout Europe. Third, the variation in surgical tech-
niques and pathology assessment between centers will most 
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certainly differ. Nevertheless, currently there is no stand-
ardized definition of ERLP for PDAC. Surgical steps and 
anatomical dissection should be standardized in future stud-
ies. Furthermore, nowadays the definition of extended distal 
pancreatectomy [18] is not yet integrated with the definition 
of radical left pancreatectomy [15] for patients with PDAC.
It is expected that standardized surgical techniques and 
standardized pathology assessment and reporting will be a 
step forward in obtaining homogeneous data from different 
centers. The European Consortium on Minimally Invasive 
Pancreatic Surgery (E-MIPS) is currently performing the 
DIPLOMA-trial (Distal Pancreatectomy, Minimally Inva-
sive or Open, for Malignancy; www.e-mips.com/diplo ma-
trial ) in Europe and the USA. DIPLOMA aims to assess 
the oncological non-inferiority of minimally invasive vs 
open distal pancreatectomy for PDAC using a standardized 
surgical technique and pathology assessment and reporting. 
Patients with PDAC of the pancreatic body or tail, requir-
ing a multivisceral resection, without the need to perform a 
vascular resection, are also included in this trial. This study 
is expected to provide additional insights on the merits of 
L-ERLP.
In conclusion, this international multicenter retrospec-
tive propensity-score matched cohort study suggests com-
parable outcomes of the laparoscopic compared to the open 
approach for ERLP, despite the high conversion rate and 
lower lymph node retrieval.
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